CD34 and myeloproliferative disorder: Nonetheless, a multicenter study of the ELN iMDSFlow WG, published in 2023, confirmed that a percentage of ≥3% marrow myeloid progenitors (CD45weak/SSClow/CD34+/CD19) strongly suggests the existence of MDS or myelodysplastic/myeloproliferative neoplasms (MDS/MPN) (77).